Zhejiang ChiMin Pharma Stages $47 Million IPO in Shanghai

Zhejiang ChiMin Pharma recently completed an IPO on the Shanghai Stock Exchange, raising $47.4 million. The company specializes in generic IV solution drugs. ChiMin has been designated a National Hi-Tech Company. The transaction shows that China's stock exchanges are not completely closed to life science initial public offerings, even though they seem to occur only infrequently. More details.... Stock Symbol: (SHA: 603222) Share this with colleagues: // //